Weve really been trying to balance getting people the care that they need and the benefits theyre looking for while also trying to make sure that its not just some kind of crazy pseudoscience, said Stefanie Morgan, the companys vice president of research
In terms of the trial rationale, studies with GLP-1 receptor agonists have shown very consistently a dose-response effect on body weight loss with higher dosages, and once-daily formulations of semaglutide 7 mg and 14 mg have been approved for the treatment of type 2 diabetes and does provide clinically relevant weight loss, said Julio Rosenstock, MD, Director of Velocity Clinical Research at Medical City Dallas and Clinical Professor of Medicine at the University of Texas (UT) Southwestern
During switching from Ozempic to Mounjaro, clinicians focus on safety and gradual adjustment rather than speed
The medications and therapeutic strategies discussed may not be suitable for everyone and can have significant risks and side effects
10.1016/S0140-6736(20)32230-3 72 IngoldI.BerndtC.SchmittS.DollS.PoschmannG.BudayK.et al (2018)
